Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents

Abstract

Glycosides of diacylglycerol, e.g. 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (GOPO), which was isolated from extracts of rose-hips by activity guided fractionation, can be used as an oral anti-inflammatory agent for the treatment of inflammatory diseases such as arthritis and osteoarthrosis.

1 - 21 . (canceled)  
     
     
         22 . A standardised product derived from rose hip material, comprising a predetermined amount of an active ingredient defined by the compound of the formula I:  
       
         
           
           
               
               
           
         
       
       wherein R and R 1  independently are selected from hydrogen, C 10-24 -alkyl, and C 10-24 -acyl, said alkyl and acyl groups having 0 to 5 unsaturated bonds, and R 1 , R 2 , R 3  and R 4  independently are selected from hydrogen and glycoside moieties, with the proviso that not both of R and R 1  are hydrogen:  
     
     
         23 . The standardised product according to  claim 22 , wherein the active ingredient is 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (GOPO).  
     
     
         24 . The standardised product according to  claim 22 , wherein the active ingredient is provided in a predetermined unit dose form in the range of 0.01-500 mg/kg body weight.  
     
     
         25 . The standardised product according to  claim 22 , wherein the active ingredient is provided in a predetermined unit dose form in the range of 0.001-50 mg/kg body weight.  
     
     
         26 . The standardised product according to  claim 22 , wherein the product is prepared in the form of unit dose forms each comprising a predetermined amount of the active ingredient, and wherein the predetermined amount of the active ingredient is provided by a quantity of a batch, said quantity being determined as the predetermined amount of the active ingredient divided by the concentration of the active ingredient in said batch.  
     
     
         27 . A standardised product according to  claim 22  comprising a purified compound of the formula I.  
     
     
         28 . A pharmaceutical composition comprising: 
 (i) a standardised product according to  claim 22;     (ii) an antioxidant; and    (iii) a pharmaceutically acceptable carrier.    
     
     
         29 . The pharmaceutical composition according to  claim 28  comprising one or more purified compound(s) in the form of 3-β-D-galactopyranosyloxy-2-(octadeca-9Z,12Z,15Z-trienoyloxy)propanyl octadeca-9Z,12Z,15Z-trienoate (GOPO) or as defined in said formula I.  
     
     
         30 . The pharmaceutical composition according to  claim 29 , wherein the one or more purified compound(s) is included in the amount of 0.1-50% by weight in the composition.  
     
     
         31 . The pharmaceutical composition according to  claim 28 , wherein the alkyl and acyl groups have 1 to 3 unsaturated carbon-carbon bonds.  
     
     
         32 . The pharmaceutical composition according to  claim 31  wherein the alkyl and acyl groups have 2 to 3 unsaturated carbon-carbon bonds.